Table 5 Characterisitics of patients and corresponding PDXs
| Â | Clinical history | Prior treatment | Days to initial tumor growth | Cell line generation |
|---|---|---|---|---|
TKO-001 | PDX from biopsy specimens of hepatic metastasis in a 72-year-old hispanic male | Surgical resection cisplatin and etoposide with good response Platinum sensitive recurrence retreated with platinum/etoposide salvage therapy with irinotecan | 335 | No |
TKO-002 | PDX from biopsy of hepatic metastasis from a female white patient | Frontline carboplatin/etoposide with tumor response after two cycles and progression after the fourth cycle Single agent etoposide Topotecan | 49 | Yes |
TKO-003 | PDX from bronchoscopic biopsy samples obtained from a paratracheal mass and subcarinal lymph node metastasis in a 71-year-old African American male | Initial diagnosis of limited stage SCLC treated with combined radiation and cisplatin/etoposide. Following recurrence 2Â years later of his platinum sensitive disease, he was retreated with carboplatin/etoposide and more recently was treated with topotecan prior to study enrollment | 135 | No |
TKO-004 | Â | Â | No growth | No |
TKO-005 | PDX developed using bronchoscopic biopsy samples obtained from a left lower lung nodule in a 50Â year old African American male | Previously treated with combined radiation and cisplatin/etoposide for limited stage SCLC. Patient had disease progression more than 6Â months after completion of chemoradiation and had no other systemic therapy prior to coming on this clinical trial when the biopsy was obtained to generate the PDX | 103 | No |
TKO-006 | Â | Â | No growth | No |
TKO-007 | Â | Â | No growth | No |
TKO-008 | PDX generated using lung biopsy from a 76-year-old male Caucasian patient | Previously treated with carboplatin/etoposide for six cycles. He subsequently received paclitaxel for progressive disease that occurred 4Â months after completing frontline therapy | 239 | No |
TKO-009 | Â | Â | No growth | No |